3,7-diamino-10H-phenothiazine salts and their use

WO2007110627

Research output: Patent

6 Downloads (Pure)

Abstract

This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R.sup.1 and R.sup.9 is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).
Original languageEnglish
Patent numberUS7,888,350
Publication statusPublished - 15 Feb 2011

Fingerprint

Salt
Drugs
Alzheimer's Disease
Invention

Cite this

@misc{b204098028694632a89c0e36c6eff702,
title = "3,7-diamino-10H-phenothiazine salts and their use: WO2007110627",
abstract = "This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R.sup.1 and R.sup.9 is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).",
author = "Wischik, {Claude Michel} and Rickard, {Janet Elizabeth} and Harrington, {Charles Robert} and David Horsley and Storey, {John Mervyn David} and Colin Marshall and Sinclair, {James Peter} and Thomas Baddeley",
year = "2011",
month = "2",
day = "15",
language = "English",
type = "Patent",
note = "US7,888,350",

}

TY - PAT

T1 - 3,7-diamino-10H-phenothiazine salts and their use

T2 - WO2007110627

AU - Wischik, Claude Michel

AU - Rickard, Janet Elizabeth

AU - Harrington, Charles Robert

AU - Horsley, David

AU - Storey, John Mervyn David

AU - Marshall, Colin

AU - Sinclair, James Peter

AU - Baddeley, Thomas

PY - 2011/2/15

Y1 - 2011/2/15

N2 - This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R.sup.1 and R.sup.9 is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).

AB - This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R.sup.1 and R.sup.9 is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: --H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).

M3 - Patent

M1 - US7,888,350

ER -